French Orthopedic Pioneer Movmedix Enters U.S. Market Following FDA 510(k) Clearance of LARS® ACJ Synthetic Ligament System
核心洞察
Movmedix received its first FDA 510(k) clearance for the LARS® ACJ system (搜索), enabling U.S. commercial launch of its synthetic ligament technology for acromioclavicular joint injuries.
The LARS® platform has been implanted in over 250,000 patients worldwide across 11 clinical indications, supported by more than 100 peer-reviewed publications over three decades.
ACJ dislocations represent 10% of all shoulder injuries in urban populations and up to 40–50% of shoulder injuries in contact-sport athletes, with an incidence of 9.2 per 1,000 person-years among young athletes.
Movmedix, the French orthopedic MedTech company headquartered near Dijon, France, announced on July 6, 2026 that it has received its first 510(k) clearance from the U.S. Food and Drug Administration (FDA), enabling the commercial launch of its LARS® ACJ system (搜索) in the United States. The clearance marks the American debut of one of the world's most established synthetic ligament technologies—a platform that has transformed ligament reconstruction and reinforcement across multiple anatomical indications for more than three decades.
The LARS® ACJ Implant is a third-generation synthetic device made from biocompatible polyethylene terephthalate (搜索) (PET). It is designed as a knitted surgical scaffold in the form of a band intended to provide fixation during the healing process following syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruptions. The device system also includes LARS® Screws and dedicated surgical instruments.
A Platform with Decades of Clinical Evidence
While this first clearance specifically addresses acromioclavicular (ACJ) joint injuries, it represents far more than the approval of a single shoulder device. Today, LARS® technologies support over 11 clinical indications, have been implanted in more than 250,000 patients worldwide, and are supported by over 100 peer-reviewed scientific publications, making Movmedix one of the most extensively documented innovators in synthetic ligament reconstruction and reinforcement.
At the heart of Movmedix's success lies its proprietary LARS® free-fiber technology, particularly recognized in knee ligament reconstruction. Unlike conventional synthetic grafts, the platform has demonstrated decades of clinical experience across multiple orthopedic applications. The newly cleared shoulder indication therefore represents the first U.S. regulatory milestone for a much broader portfolio.
Addressing a Growing Public Health Challenge
Ligament injuries have become one of the fastest-growing challenges in musculoskeletal health. In the United States alone, more than 200,000 ACL injuries occur every year, many affecting young athletes, military personnel, and physically active adults. Recovery often requires months of rehabilitation while significantly increasing the lifetime risk of osteoarthritis, generating billions of dollars in healthcare and productivity costs.
Among these injuries, acromioclavicular joint (ACJ) dislocations are common, representing 10% of all shoulder injuries in an urban population. Up to 40–50% of shoulder injuries in athletes participating in contact sports such as football, rugby, ice hockey, and wrestling involve the AC joint. The incidence among young athletes is approximately 9.2 per 1,000 person-years, with the highest risk observed in males and those participating in collision sports.
Leadership Perspective and Commercial Strategy
"Mobility is one of the greatest determinants of long-term health and quality of life," said Hervé Legrand, Chief Executive Officer of Movmedix. "Receiving our first FDA clearance validates years of investment in clinical science, manufacturing excellence and regulatory expertise. More importantly, it allows us to bring decades of French innovation in ligament reconstruction and reinforcement to American surgeons and their patients."
Since 2021, Movmedix has entered a new phase of growth, generating tens of millions of euros in annual revenue, increasing its net profit fivefold, and expanding its commercial footprint to 36 countries across Europe, Asia-Pacific, Latin America, and the Middle East, with China remaining its largest market.
Following FDA clearance, Movmedix is preparing its entry into the U.S. market through a phased commercial strategy. The company intends to establish a local presence and develop strategic partnerships to support the adoption of its technologies, while engaging with leading orthopedic surgeons and sports medicine specialists to advance clinical education and market development.
A Broader Regulatory Roadmap
The FDA clearance of LARS® ACJ also represents the beginning of a broader regulatory roadmap, with additional products from the LARS® portfolio already planned for future FDA submissions. "Our expertise has always extended well beyond one anatomical indication," added Legrand. "The FDA clearance is the first step in bringing our complete vision of ligament reconstruction to the United States."
"Our ambition is not simply to enter the U.S. market," concluded Legrand. "Our ambition is to contribute to the future of ligament reconstruction by combining French engineering excellence with scientific evidence and close collaboration with surgeons worldwide."